ABT vs HSTM: fair value comparison
Abbott Laboratories and HealthStream, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, HSTM currently sits closer to the top of our discount ranking. ABT carries the stronger quality grade.
| ABT | HSTM | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $101.95 | $29.67 |
| 12-month range | $87.78–$128.01 | $20.34–$29.67 |
| Sector rank | #35 of 113 Healthcare | #34 of 113 Healthcare |
| Quality grade | B | D |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | — | Undervalued |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: ABT fair value analysis · HSTM fair value analysis